Sitaula Seema, Pokhrel Shree Ram, Paudel Prayash, Shrestha Aabha
Department of Dermatology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Bachelor of Medicine Bachelor of Surgery, Maharajgunj Medical Campus, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
J Cosmet Dermatol. 2025 May;24(5):e70246. doi: 10.1111/jocd.70246.
Melasma is a long-term acquired disorder characterized by symmetrical darkening in facial regions exposed to sunlight. Although some risk factors have been identified, the etiology remains unclear, and interventions frequently do not totally improve outcomes.
It compares the efficacy and side effects of platelet-rich plasma therapy administered by microneedling versus microinjection to detect any difference in the delivery methods, treatment outcomes, and safety profiles.
In this prospective, single-center, randomized split-face research, 62 patients' melasma was treated with PRP therapy using microneedling versus microinjection. Microneedling and microinjection were used to apply PRP to the face's two sides. Photographs were obtained before therapy, and the modified Melasma Area and Severity Index (MASI), Physician Global Assessment, and Patient Global Assessment were used for monthly follow-up evaluation. In order to compare safety and efficacy, adverse events were recorded and statistical analysis was performed.
A significantly significant difference (p < 0.001) was observed in the mean change in MASI score between microinjection and microneedling. The microneedling group showed a 73.33% improvement while the microinjection group had an 18.33% improvement, both of which were greater than 50%. The microneedling group showed a 46.67% improvement and the microinjection group had a 5% improvement of over 75%. There were no noteworthy negative effects observed.
PRP therapy with microneedling is superior to microinjection in treating melasma; patients who receive microneedling show noticeably better improvement.
黄褐斑是一种长期获得性疾病,其特征为暴露于阳光下的面部区域出现对称性色素沉着。尽管已确定了一些危险因素,但其病因仍不清楚,且干预措施常常不能完全改善治疗效果。
比较微针注射与微量注射富血小板血浆疗法的疗效和副作用,以检测给药方式、治疗效果和安全性方面的差异。
在这项前瞻性、单中心、随机半脸研究中,对62例黄褐斑患者采用微针注射与微量注射富血小板血浆疗法进行治疗。微针注射和微量注射分别应用于面部两侧。在治疗前拍照,并使用改良的黄褐斑面积和严重程度指数(MASI)、医生整体评估和患者整体评估进行每月随访评估。为比较安全性和疗效,记录不良事件并进行统计分析。
微针注射组和微针组在MASI评分的平均变化上存在显著差异(p<0.001)。微针组改善率为73.33%,微量注射组为18.33%,两组改善率均超过50%。微针组改善率超过75%的比例为46.67%,微量注射组为5%。未观察到明显的不良反应。
微针注射富血小板血浆疗法在治疗黄褐斑方面优于微量注射;接受微针注射的患者改善效果明显更好。